Drugs / γδ T cell
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03183232 | Jun 2017 → Jun 2018 | lung cancer | Fuda Cancer Hospital, Guangzhou | Completed | No outcome recorded |
| Phase 1/2 | NCT03183219 | Jun 2017 → Jan 2018 | liver cancer | Fuda Cancer Hospital, Guangzhou | Completed | No outcome recorded |
| Phase 1/2 | NCT02418481 | Apr 2015 → Jun 2016 | breast cancer | Fuda Cancer Hospital, Guangzhou | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | γδ T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03183219 ↗ |
| Modality | Cell therapy | “γδ T cells will be used against breast tumor.” NCT02418481 ↗ |